Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Q4 2018 value amounting to $18.1 million.

  • Neurocrine Biosciences' Non-Current Deffered Revenue rose 7705.01% to $18.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $18.1 million, marking a year-over-year increase of 7705.01%. This contributed to the annual value of $18.1 million for FY2018, which is 7705.01% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Non-Current Deffered Revenue stood at $18.1 million for Q4 2018, which was up 7705.01% from $12.1 million recorded in Q3 2018.
  • In the past 5 years, Neurocrine Biosciences' Non-Current Deffered Revenue ranged from a high of $18.1 million in Q4 2018 and a low of $1.9 million during Q4 2014
  • Over the past 5 years, Neurocrine Biosciences' median Non-Current Deffered Revenue value was $10.2 million (recorded in 2015), while the average stood at $9.1 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Non-Current Deffered Revenue tumbled by 529.77% in 2014 and then skyrocketed by 44507.19% in 2015.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Non-Current Deffered Revenue stood at $1.9 million in 2014, then surged by 445.07% to $10.2 million in 2015, then changed by 0.0% to $10.2 million in 2016, then changed by 0.0% to $10.2 million in 2017, then skyrocketed by 77.05% to $18.1 million in 2018.
  • Its Non-Current Deffered Revenue was $18.1 million in Q4 2018, compared to $12.1 million in Q3 2018 and $10.2 million in Q2 2018.